HONZ(SZ:300086) Xin Lang Cai Jing·2025-10-24 07:26Core Viewpoint - Kangzhi Pharmaceutical experienced a decline of 5.02% on October 24, with a stock price of 7.19 CNY per share and a total market capitalization of 3.272 billion CNY [1] Company Overview - Kangzhi Pharmaceutical Co., Ltd. is located in Haikou National High-tech Industrial Development Zone, Hainan Province, and was established on January 20, 1994. The company was listed on May 26, 2010 [1] - The main business involves the research, production, and sales of children's medicine, maternal and infant health products, and medical protective equipment, positioning itself as a leading domestic enterprise in children's health [1] - The revenue composition of the main business includes: children's medicine 76.16%, adult medicine 20.89%, and other (supplements) 2.94% [1] Shareholder Information - Noan Fund has a presence among the top ten circulating shareholders of Kangzhi Pharmaceutical, with its Noan Multi-Strategy Mixed A Fund (320016) newly entering the top ten in the second quarter, holding 1.9087 million shares, accounting for 0.43% of circulating shares [2] - The estimated floating loss for the fund today is approximately 725,300 CNY [2] - The Noan Multi-Strategy Mixed A Fund was established on August 9, 2011, with a current scale of 1.399 billion CNY. Year-to-date returns are 67.98%, ranking 251 out of 8,154 in its category; the one-year return is 83.68%, ranking 93 out of 8,025; and since inception, the return is 224.2% [2] Fund Manager Information - The fund managers of Noan Multi-Strategy Mixed A are Kong Xianzheng and Wang Haichang. As of the report, Kong has been in position for 4 years and 333 days, managing a total fund size of 4.607 billion CNY, with the best return during his tenure being 83.16% and the worst being -16.74% [3] - Wang has been in position for 3 years and 95 days, managing a total fund size of 2.529 billion CNY, with the best return during his tenure being 70.27% and the worst being -18.8% [3]